Navigating Named Patient Import Regulations

Named Patient Import (NPI) is a regulatory mechanism that allows physicians to legally obtain and import medicines that are not yet approved or registered in the patient's home country. This pathway is typically reserved for patients who have life-threatening or seriously debilitating conditions and have exhausted all approved treatment options available locally.

The legal basis for Named Patient Imports varies by jurisdiction, but generally requires a strict documentation trail to prevent misuse. Essential requirements typically include:

• Physician's Prescription: A formal request detailing the patient's clinical condition and the specific unregistered drug required.
• Medical Justification: Documentation explaining why approved alternatives are unsuitable or have failed.
• Patient Informed Consent: A signed statement from the patient or guardian acknowledging the experimental or unregistered nature of the drug.
• Import License/Permit: Clearance issued by the local health authority (e.g., FDA or Ministry of Health) allowing the entry of the drug.

Hospitals and clinics play a critical role in facilitating NPI. They must coordinate with authorized pharmaceutical exporters, verify the licensing status of the source, ensure temperature-controlled storage upon arrival, and maintain strict pharmacy logs for audit purposes.

Working with experienced global exporters who understand the regional paperwork and customs processes is the single best way to reduce lead times. Delays at customs can not only compromise patient care but also risk the integrity of temperature-sensitive medications.